PartnerRe Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

PartnerRe Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,640	Closed	-$130K	–	398
2016 Q1	$130K	Hold	1,640	–	–	0.07%	231
2015 Q4	$206K	Sell	1,640 -2,788	-63%	-$337K	0.11%	144
2015 Q3	$461K	Buy	4,428 +25	+0.6%	+$3.21K	0.08%	180
2015 Q2	$544K	Sell	4,403 -719	-14%	-$90.6K	0.1%	167
2015 Q1	$604K	Hold	5,122	–	–	0.1%	178
2014 Q4	$608K	Buy	5,122 +765	+18%	+$86.2K	0.1%	173
2014 Q3	$489K	Sell	4,357 -665	-13%	-$63.3K	0.1%	177
2014 Q2	$475K	Sell	5,022 -676	-12%	-$47.4K	0.08%	211
2014 Q1	$403K	Buy	5,698 +71	+1%	+$5.62K	0.07%	261
2013 Q4	$418K	Sell	5,627 -307	-5%	-$21.4K	0.07%	238
2013 Q3	$450K	Buy	+5,934	New	+$472K	0.08%	225

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PartnerRe Asset Management's VRTX Position: Q2 2016 in Review

PartnerRe Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 1,640 shares — an estimated $130K sold.

PartnerRe Asset Management first reported a position in VRTX in Q3 2013 and held it in 11 quarters. The position peaked at $608K in Q4 2014. 483 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

PartnerRe Asset Management reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
PartnerRe Asset Management sold 1,640 Vertex Pharmaceuticals shares in Q2 2016, an estimated $130K.
PartnerRe Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 11 quarters.
PartnerRe Asset Management's Vertex Pharmaceuticals position peaked at $608K in Q4 2014.
483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on PartnerRe Asset Management's 13F filing for Q2 2016, filed 14 Jul 2016.